JP2011529084A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011529084A5 JP2011529084A5 JP2011520233A JP2011520233A JP2011529084A5 JP 2011529084 A5 JP2011529084 A5 JP 2011529084A5 JP 2011520233 A JP2011520233 A JP 2011520233A JP 2011520233 A JP2011520233 A JP 2011520233A JP 2011529084 A5 JP2011529084 A5 JP 2011529084A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- sequence
- acid residue
- covalently linked
- amyloid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000539 amino acid group Chemical group 0.000 claims 104
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 30
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 30
- 229930182817 methionine Chemical group 0.000 claims 30
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical group CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 28
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 26
- 239000004474 valine Substances 0.000 claims 26
- 235000004279 alanine Nutrition 0.000 claims 24
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical group CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 23
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Chemical group CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 23
- 229960000310 isoleucine Drugs 0.000 claims 23
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical group C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 21
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical group CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 19
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical group CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 19
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Chemical group OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 19
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical group OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 18
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical group NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 17
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical group CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 17
- 150000001413 amino acids Chemical group 0.000 claims 15
- 239000004471 Glycine Chemical group 0.000 claims 13
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical group OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 12
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Chemical group OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 12
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims 9
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 9
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 8
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Chemical group OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 8
- 206010002022 amyloidosis Diseases 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 4
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 4
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 claims 4
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 4
- 239000000816 peptidomimetic Substances 0.000 claims 4
- 239000004475 Arginine Chemical group 0.000 claims 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Chemical group OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical group NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 3
- 239000004472 Lysine Substances 0.000 claims 3
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Chemical group OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 3
- 235000009582 asparagine Nutrition 0.000 claims 3
- 229960001230 asparagine Drugs 0.000 claims 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 3
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 201000010374 Down Syndrome Diseases 0.000 claims 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical group OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 2
- 229940024606 amino acid Drugs 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical group OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical group OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical group C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Chemical group CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 1
- 239000004473 Threonine Chemical group 0.000 claims 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Chemical group OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8358908P | 2008-07-25 | 2008-07-25 | |
| US61/083,589 | 2008-07-25 | ||
| PCT/US2009/051721 WO2010011947A2 (en) | 2008-07-25 | 2009-07-24 | AMYLOID ß PEPTIDE ANALOGUES, OLIGOMERS THEREOF, PROCESSES FOR PREPARING AND COMPOSITIONS COMPRISING SAID ANALOGUES OR OLIGOMERS, AND THEIR USES |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011529084A JP2011529084A (ja) | 2011-12-01 |
| JP2011529084A5 true JP2011529084A5 (enExample) | 2012-05-31 |
Family
ID=41570887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011520233A Pending JP2011529084A (ja) | 2008-07-25 | 2009-07-24 | アミロイドβペプチド類似体、これらのオリゴマー、前記類似体またはオリゴマーを調製するためのプロセスおよび前記類似体またはオリゴマーを含む組成物ならびにこれらの使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20110092445A1 (enExample) |
| EP (1) | EP2303920A4 (enExample) |
| JP (1) | JP2011529084A (enExample) |
| CN (1) | CN102203124A (enExample) |
| CA (1) | CA2730804A1 (enExample) |
| MX (1) | MX2011000975A (enExample) |
| WO (1) | WO2010011947A2 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| KR20180058863A (ko) | 2005-11-30 | 2018-06-01 | 애브비 인코포레이티드 | 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도 |
| PT1954718E (pt) | 2005-11-30 | 2014-12-16 | Abbvie Inc | Anticorpos anti-globulómeros aβ, suas porções de ligação ao antigénio, correspondentes hibridomas, ácidos nucleicos, vectores, células hospedeiras, métodos de produção dos ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos para uso dos ditos anticorpos |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| US20100311767A1 (en) | 2007-02-27 | 2010-12-09 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
| ES2562224T3 (es) * | 2008-04-14 | 2016-03-03 | Alzinova Ab | Monómeros y oligómeros de beta amiloide estables |
| JP5722770B2 (ja) * | 2008-07-01 | 2015-05-27 | デ スタート デル ネダーランデン、フェルト．ドール デ ミニスター ファン フォルクスヘーゾンドハイド、フェルジイン アン スポルト | アミロイド折りたたみ中間体に対するワクチン |
| BR112012008346B1 (pt) | 2009-09-11 | 2021-12-21 | Vivoryon Therapeutics N.V. | Derivados heterocíclicos, seu processo de preparação, e composição farmacêutica |
| KR101831459B1 (ko) * | 2010-03-03 | 2018-04-04 | 더 유니버시티 오브 브리티시 콜롬비아 | 올리고머 특이적 아밀로이드 베타 에피토프 및 항체 |
| AU2013205000B2 (en) * | 2010-03-03 | 2015-05-28 | The University Of British Columbia | Oligomer-specific amyloid beta epitope and antibodies |
| MX336196B (es) | 2010-04-15 | 2016-01-11 | Abbvie Inc | Proteinas de union a amiloide beta. |
| WO2011156003A2 (en) | 2010-06-09 | 2011-12-15 | New York University | Peptoid and synthetic oligomers, pharmaceutical compositions and methods of using same |
| EP3533803B1 (en) | 2010-08-14 | 2021-10-27 | AbbVie Inc. | Anti-amyloid-beta antibodies |
| US20120089291A1 (en) * | 2010-10-12 | 2012-04-12 | Halder Bibhrajit | Autonomous machine control system |
| DK2646462T3 (en) | 2010-11-29 | 2017-07-03 | Akershus Univ | METHODS AND COMPOSITIONS FOR MONITORING PHAGOCYTIC ACTIVITY |
| WO2012072611A1 (de) * | 2010-11-29 | 2012-06-07 | Philipps-Universität Marburg | SYNTHETISCHE LIGANDEN FÜR HUMANE ANTI-Aβ-ANTIKÖRPER |
| EP2785364B1 (en) * | 2011-11-29 | 2019-01-09 | Proclara Biosciences, Inc. | Use of p3 of bacteriophage as amyloid binding agents |
| US20130164217A1 (en) * | 2011-12-21 | 2013-06-27 | Meso Scale Technologies, Llc | Method of diagnosing, preventing and/or treating dementia & related disorders |
| DE102012021222B4 (de) * | 2012-10-27 | 2015-02-05 | Forschungszentrum Jülich GmbH | Verfahren zur Herstellung einer nanoporösen Schicht auf einem Substrat |
| EP2746402A1 (en) * | 2013-03-12 | 2014-06-25 | Academisch Medisch Centrum | Method of prognosis of Alzheimers disease and substrates for use therein |
| EP2787347A1 (en) * | 2013-04-03 | 2014-10-08 | Affiris AG | Method for detecting Aß-specific antibodies in a biological sample |
| EP2787349A1 (en) | 2013-04-03 | 2014-10-08 | Affiris AG | Method for detecting proteinopathy-specific antibodies in a biological sample |
| DK3099296T3 (en) | 2014-01-31 | 2019-04-15 | Cognition Therapeutics Inc | ISO-INDOLINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE |
| CN107074924A (zh) * | 2014-07-07 | 2017-08-18 | 艾伯维德国有限责任两合公司 | 基于突变蛋白β淀粉样蛋白(Aβ)氨基酸序列的免疫原性产物及其用途 |
| AU2015311836B2 (en) * | 2014-09-05 | 2021-03-11 | Presympto, Inc. | Methods for detecting amyloid beta oligomers |
| ES2571055B1 (es) * | 2016-02-15 | 2016-12-28 | Araclon Biotech, S.L. | Conjugado amiloide y usos y procedimientos del mismo |
| WO2018005980A1 (en) * | 2016-07-01 | 2018-01-04 | The Scripps Research Institute | Compositions and diagnostic methods related to transthyretin amyloid diseases |
| IL270251B2 (en) | 2017-05-15 | 2025-01-01 | Cognition Therapeutics Inc | 1-Phenyl-1,1-dimethyl-2-(piperidinyl/pyrrolidinyl/piperazinyl)ethane derivatives and pharmaceutical preparations containing them |
| PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
| CN108148115A (zh) * | 2018-01-30 | 2018-06-12 | 中国药科大学 | 一种环肽合成新方法及其在药物开发中的应用 |
| WO2019246140A1 (en) * | 2018-06-18 | 2019-12-26 | Emory University | Parallel enzyme digestion for protein biomarker detection |
| CN109851660A (zh) * | 2019-03-20 | 2019-06-07 | 横琴欣健生物科技研究院有限公司 | 一种治疗老年痴呆症的多肽及其疫苗 |
| CN109912687A (zh) * | 2019-03-20 | 2019-06-21 | 横琴欣健生物科技研究院有限公司 | 一种治疗老年痴呆症的多肽药物 |
| JP7357354B2 (ja) * | 2020-02-04 | 2023-10-06 | 国立大学法人京都大学 | アミロイドβ４２架橋アナログペプチド |
| KR102767892B1 (ko) * | 2021-12-30 | 2025-02-14 | 고려대학교 산학협력단 | 신규한 단백질 변이체 및 이를 이용한 신경퇴행성 질환 치료용 조성물 |
| US12037375B2 (en) * | 2021-12-30 | 2024-07-16 | Korea University Research And Business Foundation | Protein variant and composition for treating neurodegenerative disease using the same |
| WO2026030341A1 (en) | 2024-07-29 | 2026-02-05 | Cognition Therapeutics, Inc. | Zervimesine for treating neurodegenerative disease |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994017197A1 (fr) * | 1993-01-25 | 1994-08-04 | Takeda Chemical Industries, Ltd. | ANTICORPS DIRIGE CONTRE LE β-AMYLOIDE OU UN DERIVE DE CE DERNIER ET SON UTILISATION |
| DE10101430B4 (de) * | 2001-01-13 | 2008-10-02 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Lösliche cyclische Analoga zur Modulation der Amyloidogenese |
| US20020132758A1 (en) * | 2001-01-18 | 2002-09-19 | Shell John W. | Method for identifying compounds to treat medical pathologies associated with molecular crystallization |
| US20070213512A1 (en) * | 2002-10-01 | 2007-09-13 | Krafft Grant A | Amyloid beta peptide analogs and assemblies thereof |
| DE10303974A1 (de) * | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| EP1676859A1 (en) * | 2004-12-30 | 2006-07-05 | Pevion Biotech Ltd. | Immunogenic compositions of cyclic peptides derived from the beta-amyloid peptide |
| ATE458754T1 (de) * | 2005-03-05 | 2010-03-15 | Abbott Gmbh & Co Kg | Screening-verfahren, verfahren zur aufreinigung nichtdiffundierbarer a-beta-oligomere, selektive antikörper gegen diese nichtdiffundierbaren a- beta-oligomere und verfahren zur herstellung dieser antikörper |
| MX2008006957A (es) * | 2005-11-30 | 2008-10-20 | Abbott Lab | Metodos para la preparacion de formas recombinantes de proteina beta-amiloide humana y usos de estas proteinas. |
| EP2091948B1 (en) * | 2006-11-30 | 2012-04-18 | Probiodrug AG | Novel inhibitors of glutaminyl cyclase |
-
2009
- 2009-07-24 CN CN200980137576XA patent/CN102203124A/zh active Pending
- 2009-07-24 CA CA2730804A patent/CA2730804A1/en not_active Abandoned
- 2009-07-24 WO PCT/US2009/051721 patent/WO2010011947A2/en not_active Ceased
- 2009-07-24 US US12/509,325 patent/US20110092445A1/en not_active Abandoned
- 2009-07-24 JP JP2011520233A patent/JP2011529084A/ja active Pending
- 2009-07-24 EP EP09801088A patent/EP2303920A4/en not_active Withdrawn
- 2009-07-24 MX MX2011000975A patent/MX2011000975A/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011529084A5 (enExample) | ||
| JP5179866B2 (ja) | アルツハイマー病の予防および治療方法 | |
| JP5282058B2 (ja) | アルツハイマー病の予防および治療方法 | |
| Fischer | The design, synthesis and application of stereochemical and directional peptide isomers: a critical review | |
| AU660947B2 (en) | Peptide-based inhibitors of HIV replication | |
| JP2013181034A5 (enExample) | ||
| JP2018509935A5 (enExample) | ||
| JP2004522736A5 (enExample) | ||
| JP2016512213A5 (enExample) | ||
| RU2011100125A (ru) | Соединения для лечения амилоидозов | |
| JP2017532289A5 (enExample) | ||
| JP2008530975A5 (enExample) | ||
| JP2006506942A5 (enExample) | ||
| JP2012531219A5 (enExample) | ||
| JP2009520758A5 (enExample) | ||
| JPWO2021116469A5 (enExample) | ||
| HRP20140886T1 (hr) | MUTANTI CyaA POLIPEPTIDI I POLIPEPTIDNI DERIVATI PRIKLADNI ZA DOPREMANJE IMUNOGENIÄŚNIH MOLEKULA U STANICU | |
| CN121001737A (zh) | Tau和β淀粉样肽免疫原组合物及相关方法 | |
| RU2011130796A (ru) | Пептиды c1orf59 и содержащие их вакцины | |
| JPWO2022060424A5 (enExample) | ||
| JPH10508865A (ja) | 抗炎症性活性を有するペプチド | |
| WO2021260176A1 (en) | Synthetic epitopes of betacoronaviruses | |
| RU2024129346A (ru) | Антигенные пептиды для профилактики и лечения рака | |
| WO2015169225A1 (zh) | 四分支多肽化合物及其制备方法与应用 | |
| JPWO2022031342A5 (enExample) |